Education
About Us
Working with TipRanks
Follow Us
TC Biopharm (Holdings) (TCBPY)
OTHER OTC:TCBPY
Top Page
TC Biopharm (Holdings)
(OTC:TCBPY)
Select Model
Select Model
Rating:38Underperform
Price Target:―
TC Biopharm's overall score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flow. Technical analysis indicates bearish momentum, while the absence of valuation metrics and earnings call information limits positive insights. The stock's financial instability and operational inefficiencies are major concerns.
TC Biopharm (Holdings) (TCBPY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$130.73K
Dividend YieldN/A
Average Volume (3M)10.20K
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,103,054
10 Day Avg. Volume11,877
30 Day Avg. Volume10,203
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
TC Biopharm (Holdings) Business Overview & Revenue Model
Company DescriptionTC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
How the Company Makes MoneyTC Biopharm makes money primarily through the development and commercialization of its cell-based therapeutic products. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develop or distribute its therapies, thereby receiving upfront payments, milestone payments, and royalties on sales. Additionally, TC Biopharm may engage in research collaborations or receive grants and funding from governmental or non-governmental organizations to support its research and development activities. The success of its revenue model relies heavily on the successful advancement of its therapies through clinical trials and regulatory approval processes.
TC Biopharm (Holdings) Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
30
Negative
Cash Flow
25
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
TC Biopharm (Holdings) Technical Analysis
Negative
0.20
Price Trends
0.26
Negative
0.29
Negative
1.96
Negative
Market Momentum
-0.02
Negative
44.79
Neutral
52.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCBPY, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.26, and below the 200-day MA of 1.96, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 44.79 is Neutral, neither overbought nor oversold. The STOCH value of 52.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCBPY.
TC Biopharm (Holdings) Risk Analysis
TC Biopharm (Holdings) disclosed 97 risk factors in its most recent earnings report. TC Biopharm (Holdings) reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TC Biopharm (Holdings) Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $4.15M | ― | -60.37% | ― | -100.00% | 86.75% | |
45 Neutral | $4.80M | ― | -248.95% | ― | ― | 98.45% | |
38 Underperform | $130.73K | ― | ― | ― | ― | ― | |
33 Underperform | $4.82M | ― | -254.09% | ― | -9.34% | 93.84% | |
30 Underperform | $3.65M | ― | -660.37% | ― | ― | 74.27% | |
29 Underperform | $10.73M | ― | -212.38% | ― | ― | 57.99% |
* Healthcare Sector Average
TCBPY
TC Biopharm (Holdings)
0.20
-93.08
-99.79%
BDRX
Biodexa Pharmaceuticals
6.70
-52.90
-88.76%
SLRX
Salarius Pharmaceuticals
3.89
-18.16
-82.36%
PCSA
Processa Pharmaceuticals
0.21
-1.03
-83.06%
GRI
GRI Bio
1.91
-3.98
-67.57%
ONCO
Onconetix
3.12
-418.48
-99.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.